BioWorld

March 31, 2003

Synta Steps Out Of The Shadows With $75.3M Funding For Pipeline

On its website, Synta Pharmaceuticals Inc. bills itself as the newest 10-year-old pharma firm in Boston. (BioWorld Today) Read More

Regeneron, Novartis Enter $75M Deal For IL-1 Trap Technology

Transgenic Mice Generated With Mutant Phosphorylated Synapse Test Retention Of Spatial Memory

Merck Data On Erbitux Status Appear Positive For ImClone

Acadia Raises $25M Privately To Advance Multiple Programs

Antex Filing For Bankruptcy After BioPort Buyout Fizzles

Procyon Acquiring Pharmacor If It Completes Funding Round

Other News To Note

Correction

Today's news in brief

BioWorld

BioWorld briefs for April 15, 2026.

MMP inhibitors divulged in Accure Therapeutics patent

BioWorld Science

Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...